Entrada Therapeutics, Inc. (TRDA) vs Yarrow Bioscience, Inc (YARW)

Entrada Therapeutics, Inc. and Yarrow Bioscience, Inc are both Biotechnology companies. Entrada Therapeutics, Inc. and Yarrow Bioscience, Inc are of similar size ($246.0M and $242.2M). Yarrow Bioscience, Inc grew revenue faster over the last twelve months: 1.26% against −94.1%. Entrada Therapeutics, Inc. has the higher net margin (−3,537.7% vs −3,881.5%) and the lower return on invested capital (−1,060.2% vs 0.00%). Across the 15 metrics below, Yarrow Bioscience, Inc leads on 8 and Entrada Therapeutics, Inc. on 7.

Valuation

Metric TRDA YARW Biotechnology median
P/E n/m n/m 7.88
P/S 55.50 45.00 11.47
P/B 1.11 0.98 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.02 0.74
EV/Sales 7.91 (0.89) 10.73
Earnings yield (64.29%) (80.21%) (28.84%)
Free cash flow yield (51.66%) (78.93%) (23.03%)

Profitability

Metric TRDA YARW Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (3,767.07%) (4,134.44%) 0.00%
Net margin (3,537.73%) (3,881.54%) 0.00%
Free cash flow margin (2,867.07%) (3,513.07%) 0.00%
Return on equity (54.09%) (61.40%) (57.72%)
Return on assets (44.35%) (54.77%) (49.22%)
Return on invested capital (1,060.24%) 0.00% 0.00%

Growth

Metric TRDA YARW Biotechnology median
Revenue growth (TTM) (94.10%) 1.26% 5.64%
EPS growth (last fiscal year) (306.55%) 32.26% —
Revenue growth, 5-year CAGR — (9.35%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TRDA YARW Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.89 15.26 4.73
Net debt to EBITDA 1.88 0.95 0.96

Dividend

Metric TRDA YARW Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric TRDA YARW Biotechnology median
Market cap 242.19m 246.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack